CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Current assets:
Cash and cash equivalents	$ 558,988	$ 1,659,564
Accounts receivable, net of allowance of $4,500 and $13,133 at September 30, 2019 and 2018, respectively	839,951	1,485,938
Inventories	142,629	221,369
Prepaid expenses and other current assets	604,740	635,174
Total current assets	2,146,308	4,002,045
Property and equipment, net	226,221	419,774
Other assets:
Deferred offering costs	109,698
Deposits	62,351	62,325
Goodwill	285,386	285,386
Intangible assets, net	734,771	864,203
Total Assets	3,564,735	5,633,733
Current liabilities:
Accounts payable and accrued liabilities (including related party of $5,844 at September 30, 2018)	1,616,997	965,167
Deferred revenue	628,993	1,856,693
Total current liabilities	2,245,990	2,821,860
Long term accrued liabilities	621,970	470,739
Secured convertible notes payable, net of debt issuance costs (including related party of $1,139,490 at September 30, 2018)	1,442,497	1,586,631
Secured convertible notes payable, recorded at fair value	102,777
Total liabilities	4,413,234	4,879,230
Commitments and contingencies
Applied DNA Sciences, Inc. Stockholders' (Deficit) Equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0 shares issued and outstanding as of September 30, 2019 and 2018
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 35,612,057 and 30,112,057 shares issued and outstanding as of December 31, 2018 and September 30, 2018, respectively	1,200	753
Additional paid in capital	255,962,930	249,119,833
Accumulated deficit	(256,805,589)	(248,366,083)
Applied DNA Sciences, Inc.'s stockholders' (deficit) equity	(841,459)	754,503
Noncontrolling interest	(7,040)
Total (deficit) equity	(848,499)	754,503
Total Liabilities and (Deficit) Equity	3,564,735	5,633,733
Series A Preferred Stock [Member]
Applied DNA Sciences, Inc. Stockholders' (Deficit) Equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0 shares issued and outstanding as of September 30, 2019 and 2018
Series B Preferred Stock [Member]
Applied DNA Sciences, Inc. Stockholders' (Deficit) Equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0 shares issued and outstanding as of September 30, 2019 and 2018